BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28822887)

  • 1. The changing diagnostic pathway for lung cancer patients in Shanghai, China.
    Jiang T; Ren S; Li X; Su C; Zhou C; O'Brien M
    Eur J Cancer; 2017 Oct; 84():168-172. PubMed ID: 28822887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
    Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
    Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-small cell lung cancer.
    Ettinger DS; Akerley W; Borghaei H; Chang AC; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Ganti AK; Govindan R; Grannis FW; Horn L; Jahan TM; Jahanzeb M; Kessinger A; Komaki R; Kong FM; Kris MG; Krug LM; Lennes IT; Loo BW; Martins R; O'Malley J; Osarogiagbon RU; Otterson GA; Patel JD; Pinder-Schenck MC; Pisters KM; Reckamp K; Riely GJ; Rohren E; Swanson SJ; Wood DE; Yang SC; Hughes M; Gregory KM;
    J Natl Compr Canc Netw; 2012 Oct; 10(10):1236-71. PubMed ID: 23054877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
    Zhou F; Moreira AL
    Arch Pathol Lab Med; 2016 Dec; 140(12):1331-1337. PubMed ID: 27588333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
    Kayser G
    Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
    Warth A
    Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fast diagnostic track for suspected lung cancer: A patient centered approach].
    Hardardottir H; Valdimarsdottir UA; Gudbjartsson T; Sigvaldason A; Lund SH; Aspelund T; Hansdottir S; Jonsson S
    Laeknabladid; 2017 Apr; 103(4):171-177. PubMed ID: 28401873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular predictive and prognostic markers in non-small-cell lung cancer.
    Coate LE; John T; Tsao MS; Shepherd FA
    Lancet Oncol; 2009 Oct; 10(10):1001-10. PubMed ID: 19796752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
    Pennell NA; Arcila ME; Gandara DR; West H
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():531-542. PubMed ID: 31099633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
    Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
    J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
    Rossi G; Graziano P; Leone A; Migaldi M; Califano R
    Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
    Tang Y; Fang W; Zhang Y; Hong S; Kang S; Yan Y; Chen N; Zhan J; He X; Qin T; Li G; Tang W; Peng P; Zhang L
    Oncotarget; 2015 Jun; 6(16):14209-19. PubMed ID: 25895031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.